ATE352638T1 - REVERSE ßTWO-HYBRIDß-SYSTEME - Google Patents
REVERSE ßTWO-HYBRIDß-SYSTEMEInfo
- Publication number
- ATE352638T1 ATE352638T1 AT96912683T AT96912683T ATE352638T1 AT E352638 T1 ATE352638 T1 AT E352638T1 AT 96912683 T AT96912683 T AT 96912683T AT 96912683 T AT96912683 T AT 96912683T AT E352638 T1 ATE352638 T1 AT E352638T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- methods
- rna
- reverse
- hybrid systems
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Control Of Direct Current Motors (AREA)
- Bridges Or Land Bridges (AREA)
- Dram (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Paper (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42052595A | 1995-04-11 | 1995-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE352638T1 true ATE352638T1 (de) | 2007-02-15 |
Family
ID=23666820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96912683T ATE352638T1 (de) | 1995-04-11 | 1996-04-11 | REVERSE ßTWO-HYBRIDß-SYSTEME |
Country Status (9)
Country | Link |
---|---|
US (7) | US5955280A (de) |
EP (1) | EP0830459B1 (de) |
JP (2) | JPH11502717A (de) |
AT (1) | ATE352638T1 (de) |
AU (1) | AU716893B2 (de) |
CA (1) | CA2217545A1 (de) |
DE (1) | DE69636866D1 (de) |
NZ (2) | NZ306767A (de) |
WO (1) | WO1996032503A1 (de) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ306767A (en) * | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
US5830751A (en) * | 1996-05-01 | 1998-11-03 | The Johns Hopkins University | Genetic assays and strains using human TP53 |
US6083693A (en) * | 1996-06-14 | 2000-07-04 | Curagen Corporation | Identification and comparison of protein-protein interactions that occur in populations |
US6897017B1 (en) * | 1997-01-31 | 2005-05-24 | Odyssey Thera Inc. | Vivo library-versus-library selection of optimized protein-protein interactions |
CA2205888A1 (en) | 1997-07-11 | 1999-01-11 | John J. Priatel | Complementation trap |
US5885779A (en) * | 1997-09-09 | 1999-03-23 | University Of British Columbia | Repressed trans-activator system for characterization of protein-protein interactions |
AU748358B2 (en) | 1997-11-10 | 2002-06-06 | General Hospital Corporation, The | Detection systems for registering protein interactions and functional relationships |
WO1999031509A1 (en) * | 1997-11-27 | 1999-06-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Improved method for the identification and characterization of interacting molecules using automation |
US6905818B1 (en) | 1997-11-27 | 2005-06-14 | Max-Planck-Gesellschaft Zur Forderungder Wissenschaften | Method for the identification and characterization of interacting molecules by automated interaction mating |
AU735887B2 (en) * | 1998-01-09 | 2001-07-19 | Phylogica Limited | Peptide detection method |
US6309817B1 (en) | 1998-09-30 | 2001-10-30 | Boston Medical Center Corporation | Identification of virulence determinants activators in prokaryotic pathogens |
US6203986B1 (en) * | 1998-10-22 | 2001-03-20 | Robert H. Singer | Visualization of RNA in living cells |
US6063578A (en) * | 1998-10-22 | 2000-05-16 | Signal Pharmaceuticals, Inc. | Dual reporter system and methods of use therefor |
EP2365081A3 (de) | 1999-04-12 | 2012-07-18 | Agensys, Inc. | 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird |
EP1792989A1 (de) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird |
WO2000066722A1 (en) * | 1999-04-30 | 2000-11-09 | Hybrigenics S.A. | Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof |
DE60041333D1 (de) | 1999-08-12 | 2009-02-26 | Agensys Inc | Hen prostatkrebs exprimiert wird, und deren verwendungen |
ATE417104T1 (de) | 1999-10-05 | 2008-12-15 | Agensys Inc | G protein-gekoppelter in prostatakrebs hochexprimierter rezeptor und seine verwendungen |
US6790607B1 (en) * | 1999-10-07 | 2004-09-14 | Hybrigen, Inc. | Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
DE19957065B4 (de) * | 1999-11-26 | 2005-01-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Screening-Verfahren für Arzneistoffe |
US20030211495A1 (en) * | 2000-03-08 | 2003-11-13 | Richard Hopkins | Reverse n-hybrid screening method |
WO2001066787A1 (en) * | 2000-03-08 | 2001-09-13 | Tvw Telethon Institute For Child Health Research | Improved reverse n-hybrid screening method |
AU2001245584B2 (en) * | 2000-03-08 | 2007-02-08 | Phylogica Limited | Improved reverse n-hybrid screening method |
AU2001263155A1 (en) * | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
US7029847B2 (en) | 2000-05-16 | 2006-04-18 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
US6902882B2 (en) | 2000-05-23 | 2005-06-07 | Kerong Gu | Methods of monitoring production of gene products and uses thereof |
US6406863B1 (en) * | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
EP1299727B1 (de) | 2000-07-12 | 2009-04-22 | Agensys, Inc. | Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
EP2022797A3 (de) | 2000-08-28 | 2011-11-09 | Agensys, Inc. | Nukleinsäure und entsprechendes Protein mit der Bezeichnung 85P1B3 für die Behandlung und den Nachweis von Krebs |
US6787321B1 (en) | 2000-10-13 | 2004-09-07 | The Regents Of The University Of California | Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
AU2002225623A8 (en) * | 2000-11-17 | 2009-07-30 | John G Wise | Creation and identification of proteins having new dna binding specificities |
WO2002074908A2 (en) * | 2001-03-02 | 2002-09-26 | Mds Proteomics, Inc. | Methods and reagents for regulating apoptosis |
WO2002070662A2 (en) | 2001-03-02 | 2002-09-12 | Gpc Biotech Ag | Three hybrid assay system |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
CA2443123A1 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US6841352B2 (en) | 2001-06-29 | 2005-01-11 | Myriad Genetics, Inc. | Mating-based method for detecting protein—protein interaction |
EP2053406A3 (de) * | 2001-07-16 | 2009-06-24 | caprotec bioanalytics GmbH | Capture Compounds, Sammlung derselben und Verfahren zur Proteomanalyse und Komplexzusammensetzung |
US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
AU2002332598A1 (en) * | 2001-08-22 | 2003-03-10 | Shengfeng Li | Compositions and methods for generating antigen-binding units |
JP2005505271A (ja) | 2001-09-06 | 2005-02-24 | アジェンシス, インコーポレイテッド | 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質 |
US7175983B2 (en) * | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
AU2002352602A1 (en) * | 2001-11-07 | 2003-05-19 | Curagen Corporation | General screening method for ligand-protein interactions |
US20040161753A1 (en) * | 2001-11-16 | 2004-08-19 | Wise John G. | Creation and identification of proteins having new dna binding specificities |
DE60325847D1 (de) * | 2002-03-11 | 2009-03-05 | Caprotec Bioanalytics Gmbh | Verbindungen und verfahren für die analyse des proteoms |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
CA2658334C (en) * | 2003-01-16 | 2012-07-10 | Caprotec Bioanalytics Gmbh | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
CA2860151A1 (en) | 2003-02-10 | 2004-08-26 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
CA2525250A1 (en) * | 2003-05-09 | 2004-11-25 | Health Research Inc. | Improved methods for protein interaction determination |
CN101090729B (zh) | 2003-05-30 | 2014-07-23 | 艾更斯司股份有限公司 | ***干细胞抗原(psca)变体及其序列 |
WO2005005960A2 (en) * | 2003-06-30 | 2005-01-20 | University Of Massachusetts | High throughput one-hybrid system |
EP1697534B1 (de) | 2003-12-01 | 2010-06-02 | Life Technologies Corporation | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
AU2005219441A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | ALK7 and myostatin inhibitors and uses thereof |
AU2005250370B2 (en) | 2004-05-28 | 2010-04-01 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
US8034553B2 (en) | 2004-06-24 | 2011-10-11 | Kimberly-Clark Worldwide, Inc. | Biomarkers for wound healing |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
FR2877010B1 (fr) * | 2004-10-25 | 2007-03-16 | Aventis Pharma Sa | Systeme double-hybride base sur la mise sous silence de genes par interference transcriptionnelle |
WO2006105488A2 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
US7932030B2 (en) * | 2007-04-05 | 2011-04-26 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | System for pulling out regulatory elements using yeast |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
CA2729054C (en) | 2008-06-26 | 2019-09-03 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
TW201919685A (zh) | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
US20100075326A1 (en) * | 2008-09-12 | 2010-03-25 | Cornell University | Yeast surface two-hybrid system for quantitative detection of protein-protein interactions |
AU2010232693B2 (en) | 2009-03-30 | 2016-04-21 | Acceleron Pharma Inc. | BMP-ALK3 antagonists and uses for promoting bone growth |
CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
AU2010282361B2 (en) | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
WO2011031901A1 (en) | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
EP3260130B1 (de) | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Verfahren zur behandlung von fettleber |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US20130035255A1 (en) | 2010-03-26 | 2013-02-07 | Integratech Proteomics, Llc | Controlled release hybrid systems |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
US20140378537A1 (en) | 2011-09-09 | 2014-12-25 | Genentech, Inc. | Treatment of th17 mediated inflammatory diseases |
EP3520805B1 (de) | 2011-10-17 | 2021-03-10 | Acceleron Pharma Inc. | Zusammensetzungen zur behandlung von myelofibrose |
US8903454B2 (en) * | 2011-11-07 | 2014-12-02 | Alcatel Lucent | Base station and radio unit for creating overlaid sectors with carrier aggregation |
KR102279522B1 (ko) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
JP6649895B2 (ja) | 2014-04-18 | 2020-02-19 | アクセルロン ファーマ, インコーポレイテッド | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
RS64214B1 (sr) | 2014-12-03 | 2023-06-30 | Celgene Corp | Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
MA53883A (fr) | 2015-04-06 | 2021-08-18 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
BR112017021510A2 (pt) | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
US11013781B2 (en) | 2015-07-01 | 2021-05-25 | Alk-Abelló As | Peptide combinations and uses thereof for treating grass allergy |
CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
CN108697793B (zh) | 2015-11-23 | 2023-08-01 | 阿塞勒隆制药公司 | 治疗眼睛疾病的方法 |
ES2646388B1 (es) * | 2016-05-11 | 2018-10-15 | Consejo Superior De Investigaciones Científicas (Csic) | Método de doble híbrido en reverso para la identificación de mutaciones missense |
JP7080878B2 (ja) | 2016-05-27 | 2022-06-06 | シンセックス, インコーポレイテッド | タンパク質界面 |
WO2018013936A1 (en) | 2016-07-15 | 2018-01-18 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
BR112019001615A2 (pt) | 2016-07-27 | 2019-04-30 | Acceleron Pharma Inc. | métodos e composições para tratar mielofibrose |
AU2017325973A1 (en) | 2016-09-15 | 2019-03-07 | Acceleron Pharma Inc. | Twisted gastrulation polypeptides and uses thereof |
CN116650622A (zh) | 2016-10-05 | 2023-08-29 | 艾科赛扬制药股份有限公司 | 用于治疗肾脏疾病的组合物和方法 |
EP3523328A4 (de) | 2016-10-05 | 2020-04-01 | Acceleron Pharma Inc. | Variante actriib-proteine und verwendungen davon |
KR102635723B1 (ko) | 2017-05-04 | 2024-02-08 | 악셀레론 파마 인코포레이티드 | Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도 |
WO2019099678A1 (en) * | 2017-11-16 | 2019-05-23 | Synthex, Inc. | Selective modulation of protein-protein interactions |
WO2019104244A1 (en) | 2017-11-22 | 2019-05-31 | Synthex, Inc. | Peptides for inhibiting rad51 |
JP6920978B2 (ja) * | 2017-12-18 | 2021-08-18 | 浜松ホトニクス株式会社 | 画像取得装置及び画像取得方法 |
GB201802744D0 (en) * | 2018-02-20 | 2018-04-04 | Longas Tech Pty Ltd | Method |
AU2020275425B2 (en) | 2019-05-15 | 2024-06-27 | Synthex, Inc. | Selective degradation of proteins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
EP0550592B1 (de) * | 1990-09-24 | 1997-01-15 | BRENT, Roger | Überprüfungsteste |
AT395385B (de) | 1990-12-13 | 1992-12-10 | Voest Alpine Krems | Tauchrohr fuer vorrichtungen zum auftrennen von stoffgemengen |
US5192238A (en) * | 1992-07-14 | 1993-03-09 | Brown John B | Self-activated man overboard recovery system |
EP0672131B1 (de) * | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | Ein neues zellzyklus kontrollprotein |
US5512473A (en) * | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5989808A (en) * | 1994-06-14 | 1999-11-23 | American Cyanamid Company | Identification of compounds affecting specific interaction of peptide binding pairs |
US6770446B1 (en) * | 1994-06-14 | 2004-08-03 | Wyeth | Cell systems having specific interaction of peptide binding pairs |
US5695941A (en) * | 1994-06-22 | 1997-12-09 | The General Hospital Corporation | Interaction trap systems for analysis of protein networks |
EP1405911A1 (de) * | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | System zur Erkennung von Protein-Interaktionen |
AU2983295A (en) * | 1994-07-22 | 1996-02-22 | Ciba-Geigy Ag | Dual hybrid system |
US5610015A (en) * | 1995-03-23 | 1997-03-11 | Wisconsin Alumni Research Foundation | System to detect protein-RNA interactions |
NZ306767A (en) * | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
US5989909A (en) * | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
-
1996
- 1996-04-11 NZ NZ306767A patent/NZ306767A/xx not_active IP Right Cessation
- 1996-04-11 CA CA002217545A patent/CA2217545A1/en not_active Abandoned
- 1996-04-11 AU AU55412/96A patent/AU716893B2/en not_active Expired
- 1996-04-11 WO PCT/US1996/004995 patent/WO1996032503A1/en active IP Right Grant
- 1996-04-11 JP JP8531174A patent/JPH11502717A/ja not_active Withdrawn
- 1996-04-11 NZ NZ502795A patent/NZ502795A/en not_active IP Right Cessation
- 1996-04-11 DE DE69636866T patent/DE69636866D1/de not_active Expired - Lifetime
- 1996-04-11 AT AT96912683T patent/ATE352638T1/de not_active IP Right Cessation
- 1996-04-11 EP EP96912683A patent/EP0830459B1/de not_active Expired - Lifetime
-
1997
- 1997-09-04 US US08/923,274 patent/US5955280A/en not_active Expired - Lifetime
- 1997-10-24 US US08/959,536 patent/US5965368A/en not_active Expired - Lifetime
-
2001
- 2001-12-21 US US10/027,219 patent/US7033768B2/en not_active Expired - Lifetime
-
2002
- 2002-03-27 US US10/107,786 patent/US20020197627A1/en not_active Abandoned
- 2002-06-26 US US10/180,235 patent/US20030068612A1/en not_active Abandoned
-
2004
- 2004-08-18 US US10/921,581 patent/US20050053913A1/en not_active Abandoned
-
2006
- 2006-02-13 US US11/352,283 patent/US7601533B2/en not_active Expired - Lifetime
- 2006-09-07 JP JP2006242341A patent/JP2007075107A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU5541296A (en) | 1996-10-30 |
US20020197627A1 (en) | 2002-12-26 |
US7601533B2 (en) | 2009-10-13 |
NZ306767A (en) | 2000-03-27 |
DE69636866D1 (en) | 2007-03-15 |
US20030068612A1 (en) | 2003-04-10 |
CA2217545A1 (en) | 1996-10-17 |
JP2007075107A (ja) | 2007-03-29 |
US5965368A (en) | 1999-10-12 |
EP0830459A4 (de) | 2002-02-27 |
WO1996032503A1 (en) | 1996-10-17 |
US20050053913A1 (en) | 2005-03-10 |
US20060223089A1 (en) | 2006-10-05 |
EP0830459A1 (de) | 1998-03-25 |
US20030124538A1 (en) | 2003-07-03 |
EP0830459B1 (de) | 2007-01-24 |
US5955280A (en) | 1999-09-21 |
JPH11502717A (ja) | 1999-03-09 |
AU716893B2 (en) | 2000-03-09 |
NZ502795A (en) | 2001-09-28 |
US7033768B2 (en) | 2006-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE352638T1 (de) | REVERSE ßTWO-HYBRIDß-SYSTEME | |
DE69534733D1 (de) | NEUARTIGE AUF p53 ANSPRECHENDE GENE | |
DE69607830T2 (de) | Verfahren zur isothermer amplifikation von nukleinsäure molekülen | |
ATE211174T1 (de) | Thymidin-kinase-mutanten | |
NO973838L (no) | DNA-molekyler, deres fremstilling samt anvendelse ved genterapi | |
RU95110871A (ru) | Способы определения нуклеотидной последовательности | |
CY1111006T1 (el) | Εκριμματαση ασθενειας alzheimer | |
ATE295429T1 (de) | Two-hybrid-screeningverfahren unter verwendung des bakteriellen transcriptionsaktivators sigma- 54 | |
DK0973928T3 (da) | DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle | |
HUP9900018A1 (hu) | Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására | |
DE69638142D1 (de) | Regulierte Gene und ihre Verwendungen | |
DE69840387D1 (de) | Nik proteine, nukleinsäure sowie verfahren | |
WO2000069896A3 (en) | Molecular interactions in haematopoietic cells | |
CA2263713A1 (en) | Lyophilization of cultured human cells to preserve rna and dna | |
WO2002040668A3 (de) | Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen | |
WO2002042422A3 (en) | Molecular interactions in hematopoietic cells | |
DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
DK0877758T3 (da) | Oprenset SR-p70-protein | |
WO1999003993A3 (en) | Suppressors of cytokine signaling; related reagents | |
WO1997024446A3 (en) | Gene delivery vehicle-targeting ligands | |
HUP9900750A2 (hu) | Gén kifejezésére szolgáló promóterek | |
ATE266731T1 (de) | Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung | |
ATE211180T1 (de) | Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit | |
PT1058739E (pt) | Metodo para produzir perfis de expressao genica | |
WO1999047673A3 (en) | Isolated mammalian membrane protein genes and related reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |